| (USD) | Jun 2024 | Q/Q |
|---|---|---|
| Revenue | 360.5MM | +0% |
| Operating Income | -701K | -102% |
| Operating Expenses | 361.2MM | - |
| Net Income | 6.5MM | -82% |
| R&D | 179.7MM | -10% |
| G&A | 138.8MM | +9% |
| Amortization | 601K | - |
| Interest Expense | 4.8MM | +16% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Investors were disappointed with Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) recent earnings release. We did some...
Both of these biotechs are highly innovative companies.
The latest analyst coverage could presage a bad day for Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ), with the analysts...
Avidity unveiled promising results for its DMD treatment on Friday and the top-notch biotech stock catapulted. RNA stock is highly rated.
Sarepta Therapeutics (SRPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Q2 2024 Sarepta Therapeutics Inc Earnings Call
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one. Last year, the ecosystem reached a valuation of $1.55 trillion. Between 2024 to 2030, the segment could expand at a compound annual growth rate (CAGR) of 13.96% to $3.88 trillion. Along this line of thinking, the current market fallout makes biotech stocks all the more intriguing. No matter what, society will always push for soluti
SRPT earnings call for the period ending June 30, 2024.